Microgenesis team has developed and validated a real-time PCR-based technology capable of translating the changes of the microbiota (the populations of microorganisms that inhabit our body in a symbiotic relationship) to determinate expression levels of microRNAs that allowed us to create the GYNOMA test. 

This platform starts from the analysis of a sample of vaginal swab that can be taken by the same patient since it is non-invasive and was designed for the greatest possible woman's comfort. Based on the study of the data obtained, GYNOMA allows accurate and early diagnosis so that a preventive treatment of the microbiota alterations can be provided. These alterations could be capable of causing changes in the functionality of the immune system and which are manifested in patients with symptoms still nonspecific of inflammation, which affect fertility and related pathologies.